MTA2 (metastasis-associated protein 2) is a component of the NuRD (nucleosome remodeling and histone deacetylation) complex. MTA2 is highly similar to MTA1 and was identified as a factor differentially expressed in a carcinoma cell line. MTA2 can repress p53-dependent transcriptional activation by enhancing its deacetylation. MTA1 has also been shown to function as a corepressor for ligand-induced estrogen receptor (ER) transactivation. As part of the NuRD complex MTA2 represses ERalpha transactivation activity by modulating the acetylation status of ERalpha.